Methodological Considerations Regarding Respiratory Safety and Recovery in Overweight or Obese Patients Undergoing Painless Gastroscopy Authors: Enjun Yan, Xinyan Wang, Qiucheng Zhao Published: 2026 Dear editor We read with great interest the randomized controlled trial by Zhang et al1 comparing ciprofol with propofol, both combined with alfentanil, for painless gastroscopy in overweight or obese patients. The study addresses an important clinical question, as respiratory adverse events remain a major concern during procedural sedation in patients with increased body mass. The lower incidence of respiratory adverse events observed with ciprofol is clinically relevant and provides useful evidence for sedative selection in this population. Several methodological considerations, however, merit further discussion regarding the interpretation and clinical applicability of these findings. First, the predefined threshold for respiratory rescue warrants further clarification. According to the study protocol, patients received oxygen via nasal cannula at 3–4 L/min, and respiratory interventions, including jaw-thrust maneuvers and mask oxygenation, were initiated when SpO2 fell below 90% and failed to recover for 15 consecutive seconds. Although predefined rescue criteria are important for standardizing the management of respiratory events across treatment groups, the rationale for selecting a 15-second observation interval is not fully described. This consideration may be particularly relevant in overweight or obese patients, who may have an increased risk of hypoxaemia during procedural sedation.2 Clarifying the rationale for this rescue threshold, as well as the circumstances warranting earlier intervention, would improve the clinical interpretability and reproducibility of the sedation protocol. Second, the body-weight scalar used for weight-based drug dosing should be clearly specified. Patients received alfentanil at 5 μg/kg followed by propofol at 2 mg/kg or ciprofol at 0.4 mg/kg. However, the body-weight scalar used to calculate these doses was not specified. In overweight or obese patients, whether weight-based dosing is based on total body weight, ideal body weight, lean body weight, or an adjusted body-weight scalar may influence drug exposure and the depth of sedation.3 Explicitly reporting the weight scalar used for each agent would therefore improve the transparency and reproducibility of the anesthetic protocol and facilitate interpretation of dosing across patients with different body compositions. Third, the binary composite endpoint may not fully characterize the frequency and cumulative burden of respiratory events. The primary endpoint was defined as the occurrence of at least one respiratory adverse event, comprising respiratory depression, hypoxemia, or apnea. Hypoxemia was defined as SpO2 <90% lasting for more than 15 seconds, respiratory depression as a respiratory rate <8 breaths/min lasting for more than 30 seconds, and apnea as the absence of thoracic movement for more than 20 seconds. Each patient was counted once in the composite endpoint regardless of the number of component events experienced. Because the primary composite endpoint was defined at the patient level, it captures whether a patient experienced at least one qualifying respiratory event but does not distinguish the frequency or cumulative burden of events within an individual patient. Thus, a patient experiencing a single qualifying episode and another experiencing repeated episodes could receive the same binary classification for the primary endpoint, despite potentially different clinical burdens.4 The study did, however, report several complementary respiratory measures. Minimum SpO2 was lower in the propofol group than in the ciprofol group, and the duration of hypoxemia was also assessed. In addition, 27 patients (50.94%) in the propofol group and 14 patients (26.42%) in the ciprofol group required at least one corrective oxygenation intervention (P=0.010). These measures provide clinically informative dimensions beyond the occurrence of a respiratory event alone. Greater integration of the frequency, duration, depth of desaturation, and need for intervention could therefore provide a more nuanced characterization of respiratory safety and better convey the clinical magnitude of differences between sedative regimens. Finally, recovery assessment based on eye opening alone may provide an incomplete measure of recovery. Recovery time was defined as the interval from completion of drug administration to eye opening. Although eye opening is a practical marker of emergence from sedation, it does not necessarily encompass broader dimensions of recovery, such as sustained respiratory stability, orientation, motor function, or readiness for discharge.5 Future studies comparing sedative regimens may therefore benefit from incorporating validated recovery or discharge-readiness criteria in addition to eye-opening time. Such an approach would provide a more comprehensive assessment of recovery following procedural sedation. In conclusion, Zhang et al provide clinically relevant randomized evidence regarding the use of ciprofol combined with alfentanil for painless gastroscopy in overweight or obese patients. Further clarification of the respiratory rescue threshold and weight-based dosing strategy, together with more comprehensive characterization of respiratory event burden and recovery, would strengthen the interpretation and reproducibility of these findings. Funding Statement This work was supported by the “1+X” Research Project at the Second Hospital of Dalian Medical University. Artificial Intelligence Statement ChatGPT (OpenAI, San Francisco, CA, USA; GPT-5.6) was used solely to improve language and grammar. All suggested revisions were reviewed and approved by the authors, who retain full responsibility for the manuscript’s scientific content. Disclosure The authors declare no conflicts of interest in this communication. References